VINTURA

## Value-Based Healthcare:

The answer to our future healthcare challenges?

HE SENSE AND NON-SENSE OF VBHC TODAY, With recommendations for tomorrow

> Gérard Klop Arno Rutte



November 4<sup>th</sup>, 2021


# VBHC - The answer to our future healthcare challenges?

The sense and non-sense of VBHC today, with recommendations for tomorrow

For the full recording click here



#### HOW CAN WE USE VBHC TODAY ...



with 'Point for Parkinson' as the central coordination point. We are now in the building an advanced ICT-system via which we can share and receive info.

VINTURA

## TO SHAPE THE VBHC OF TOMORROW

Payers need to be convinced of the 'new' end point; value. Payers however are often scared that the increased value may also increase costs, which hampers the switch to a new system. The question is if the payers want to pay for real added-value across the healthcare system, despite existing budget silos.




In elderly care, applying the pure VBHC principles is also difficult

- Comorbid and heterogenic elderly patients are not really fit for pure VBHC
- There is no single unambiguous care process
- No standardized outcomes linked to specific interventions, only holistic outcomes

50

Multimorbidity per 1000 inhabitant

Care for elderly is organized according to the job-shop model. However, a job-shop model, without coordination, leads to undertreatment, overtreatment, miscommunication, & errors



To what extent can pharma take responsibility for patient-relevant outcomes?

In the below 3 situations, pharma can take accountability for patient outcomes

Pharma is the only preventive or therapeutic intervention (for example in hematology)
 Pharma is at the end of a complex treatment process where patient status can be unambiguously determined.
 Pharma intervention takes place within a controlled, unambiguous care path (line model).

There are some additional conditions for pharma to take accountability for patient outcomes

- Cross-disciplinary collaboration and ownership regarding patient outcomes
- Insight in the entire patient care process, from intake (patient mix) to after-care
- Clear understanding of pharma intervention factors influencing patient – outcomes
- Integrated infrastructure for data registration, processing and data access


As an alternative to patient outcomes measurement, pharma could consider measuring surrogate outcomes or patient response/non-response measurement

VBHC requires pharma to make a clear strategic choice and definition of its role in the healthcare system

We cannot afford this inefficiency and can overcome this by

organizing in a hub-and-spoke model. Ultimately, we need to

coordinate across multiple diseases, to achieve VMHC at large



#### Improving & integrating care

IN ELDERLY CARE SIGNIFICANT VALUE

CAN BE CREATED

WITH VMHC Coordinating care around one or

multiple medical

- Co-develop care optimization solutions
- Be a constant partner in continuous care improvement
- Developing or acquiring disease management services

#### Measuring outcome

- Pharma only intervention: real patient outcome
- Within controlled setting: real patient outcome
- Complex setting: surrogate
  outcome or response rate

VMHC is pertinent in oncology. We currently use a line model for distinct patient segments. With innovative treatments, and a view of cancer as a more chronic condition, we are moving from a curative approach for cancer to a more holistic view including quality of life. The hub-and-spoke or coordination model will help (often heterogeneous) patients navigate the healthcare system.

NHS England and Novartis are collaborating to remove the bottlenecks for a population of CVD patients at high risk. We now have one aligned objective and are identifying patients with the highest need. We are removing hurdles that limit access innovative treatments and are measuring and improving outcomes.



## WHERE TO GO FROM HERE?

**VBHC** 

VBHC: TARGETED IMPLEMENTATION based on disease and patient characteristics

VMHC: BROAD IMPLEMENTATION especially for comorbid, chronic and elderly patients. With a trusted third party as independent care coordinator

f we work together across the healthcare ecosystem, we can make it a reality.

There is no time to wait.



VBHC theory made me aware of the strange way in which we work. This allowed us to achieve more patient-centric work. We need to reimburse for outcomes, not for service. It's very motivating to work for value!

We need interoperable, realtime data that is transparent and can be shared between providers so we can make better decisions.

Ultimately VBHC is a winwin-win for everyone. Yet we need to understand that it may not be a win for everyone in the shortterm as well. We need to acknowledge this and find a solution to bridge it.

**VMHC** 

THE MOST O VMHC provides a A regional or More ntegrated overview ational hub-andtransparency in the **IMPORTAN1** and puts the patient a poke model is mucl care process and patient data betwee nore efficient than ADVANTAGES every healthcare viders and for ovider building its OF VMHC G Fewer Patients no longer G Lower burden on Central and broad angagement around communication) irsing and medical errors and less staff as non-medical atients, resulting in duplication staff can handle disruptive issues at th insights for care

 VMHC also O VMHC is a prelud to further automation for care (!), VBHC only with a long-term as soon as thet organises the coordination role has been physically set u ision of care and configured

ordination point VMHC is a O VMHC can be implemented quickly and yields immediate short-term solution

coordination between care providers. We need to be prepared and need to start moving. This is an invitation to everyone to join us in this journey. **IT IS TIME TO ACT NOW!** 

A lot of value can be created today by better cooperation and

The full VBHC report can be downloaded for free at www.vintura.com



© VINTURA

SPEAKERS AT THE EVENT



**EVA VILLALBA Executive Director at Quebec Cancer Coalition** 



JANNEKE VAN DER KAMP Head of Region Europe at Novartis Pharma



**TFUS VAN I AAR** Director of Research at Point for Parkinson

GÉRARD KLOP

Partner at Vintura & author of VBHC - The answer to our future healthcare challenges?



CASPER PAARDEKOOPER Partner at Vintura

For questions, please get in touch with us via www.vintura.com

